Sökning: WFRF:(Lindman H) >
PREDIX HER2 trial :
PREDIX HER2 trial : Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
-
- Hatschek, T. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
- Andersson, A. (författare)
- Norrlands University Hospital, Umeå, Sweden
-
- Bjöhle, J. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
visa fler...
-
- Bosch, A. (författare)
- Lund University, Lund, Sweden
-
- Carlsson, L. (författare)
- Länssjukhuset Sundsvall, Sundsvall, Sweden
-
- Dreifaldt, Ann Charlotte, 1964- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Örebro University Hospital,Örebro, Sweden
-
- Einbeigi, Z. (författare)
- Sahlgrenska University Hospital, Göteborg, Sweden
-
- Elinder, E. (författare)
- Södersjukhuset, Stockholm, Sweden
-
- Fredholm, H. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
- Isaksson-Friman, E. (författare)
- St Görans Hospital, Stockholm, Sweden
-
- Hellström, M. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
- Johansson, H. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
- Lekberg, T. (författare)
- Karolinska Universitetssjukhuset, Solna, Sweden
-
- Lindman, H. (författare)
- University Hospital Uppsala Akademiska Sjukhuset, Uppsala, Sweden
-
- Zerdes, I. (författare)
- Karolinska Institutet
-
- Foukakis, T. (författare)
- Radiumhemmet, Solna, Sweden
-
- Hartman, J. (författare)
- Södersjukhuset, Stockholm, Sweden
-
- Brandberg, Y. (författare)
- Karolinska Institutet, Stockholm, Sweden
-
- Bergh, J. (författare)
- Karolinska Institutet - Bioclinicum, Solna, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2020
- 2020
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier. - 0923-7534 .- 1569-8041. ; 31:Suppl. 2, s. S49-S49
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://www.annalsofo...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Neoadjuvant treatment with Trastuzumab-emtansine was associated with similar rates of pathological complete remission (pCR) as standard therapy withd ocetaxel, trastuzumab and pertuzumab in the PREDIX HER2 trial. Here, results of event-free survival (EFS), and pCR rates in key clinical-pathological subgroups and biomarkers including the abundance of stromal tumor infiltrating lymphocytes (TILs) are presented.Methods: PREDIX HER2 is a randomized, multicenter, open-label, phase 2 study involving 9 Swedish sites. Patients with HER2 positive breast cancer, verified by ISH, T>20 mm and/or verified lymph node metastases were randomized to six three-weekly courses of either docetaxel, trastuzumab SC and pertuzumab (group A), or trastuzumab emtansine (T-DM1, group B). Switch of treatment to the opposite arm was allowed in case of lack of response or severe toxicity. Radiological evaluation included 18F-FDG PET/CT. Patients in both groups received adjuvant chemotherapy with epirubicin and cyclophosphamide. TILs were evaluated using standard methodology, median 10%.Results: In total 197 pts. were evaluable, 99 in group A, and 98 in group B. pCR (ypT0/is ypN0) was achieved in 90 pts, 45.7%, with no significant difference between the two treatment groups. pCR rates were lower in the group of patients with hormone receptor (HR)epositive compared with HR-negative tumors but similar in both treatment groups. pCR rates did not differ between the two treatments in subgroups defined by age, menopausal status, tumor grade, T size, node status, HR-status, HER2 status and Ki67. Progressive disease was observed in 3 pts. (3%) during treatment with T-DM1, none in group A. After a median follow-up of 2.4 years 13 EFS events occurred, with no significant differences between the treatment groups. The presence of 10% TILs predicted pCR significantly (p¼0.009), similar in both treatment groups. We also found that a decrease of SUVmax by more than 80% was highly predictive of pCR. HRQoL was significantly better in pts. receiving T-DM1.Conclusions: Our data suggest that neoadjuvant T-DM1 may be as effective as standard neoadjuvant treatment in all clinical subgroups evaluated. Both TILs and PET/CT showed potential to predict pCR.Clinical trial identification: NCT02568839.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hatschek, T.
-
Andersson, A.
-
Bjöhle, J.
-
Bosch, A.
-
Carlsson, L.
-
Dreifaldt, Ann C ...
-
visa fler...
-
Einbeigi, Z.
-
Elinder, E.
-
Fredholm, H.
-
Isaksson-Friman, ...
-
Hellström, M.
-
Johansson, H.
-
Lekberg, T.
-
Lindman, H.
-
Zerdes, I.
-
Foukakis, T.
-
Hartman, J.
-
Brandberg, Y.
-
Bergh, J.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Örebro universitet
-
Karolinska Institutet